# MS DCF Valuation — Investment Banking Valuation Memo
**Date: 2026-09-11 (Friday), ~10:15 ET (verified via `TZ=America/New_York date`) — price-roll and rate-sensitivity update on all six holdings; no full rebuild warranted this cycle (no fundamental/structural change on any name since yesterday's builds).**

*Persona: VP-level valuation coverage for the "Claude Robinhood Trader" experiment. Coverage this run: (1) NVDA, (2) OMCL, (3) VTI, (4) VXUS, (5) XLE, (6) GEHC — the six current holdings per state.md's 2026-09-11 ~09:36 ET live Robinhood snapshot (NVDA $219.4915, VTI $377.10, VXUS $87.205, OMCL $32.88, XLE $64.97, GEHC $64.975). GS's 2026-09-11 ~09:44 ET report confirms its screener rank-1 slot is still XLE (already held) — no separate not-held name requires a build this cycle. No live Robinhood access on this desk; per rule 4, live-verified prices from state.md take precedence over WebSearch for the six holdings.*

---

## Verdicts (top line)

| Ticker | Current Price | DCF Fair Value (base case) | Verdict |
|---|---|---|---|
| **GEHC** | $64.975 (state.md, 9/11 ~09:36 ET, +1.14% on the day, back above the $65 revisit line) | $71.16/sh (WACC 8.5%, g 3% — rebuilt 9/10, unchanged) | **UNDERVALUED, gap ≈ +9.5%**, narrowing slightly from 9/10's +10.8% purely on today's price recovery. **No trim, no add.** |
| **NVDA** | $219.4915 (state.md, 9/11 ~09:36 ET, +0.52%) | ~$206.2 (WACC 11%, g 3% — unchanged since 8/27) | **MILDLY OVERVALUED — ~6.1% downside to base case**, essentially flat vs. 9/10's ~5.8%. |
| **OMCL** | $32.88 (state.md, 9/11 ~09:36 ET, +1.95% on a wide bid/ask — $32.88/$33.21, flagging the spread per rule 4) | ~$53.89 (WACC 9%, g 3%, unchanged since 7/30) | **UNDERVALUED — ~63.9% upside**, a new widest-recorded discount on this name, up from 9/10's ~62.9%. |
| **VTI** | $377.10 (+1.03%) | N/A — no single-company DCF applies | **NOT APPLICABLE / HOLD BY CONSTRUCTION.** Unchanged. |
| **VXUS** | $87.205 (+1.07%) | N/A — no single-company DCF applies | **NOT APPLICABLE / HOLD BY CONSTRUCTION.** Unchanged. |
| **XLE** | $64.97 (+0.06%, essentially flat) | ≈ $58.9/sh (two-name weighted composite, CVX + XOM, WACC 10.5%, g 1.5% — rebuilt 9/9, price-rolled since) | **OVERVALUED, gap ≈ -10.3%**, essentially flat vs. 9/10's -10.1%. **No trim (hedge thesis intact), no add.** |

**Bottom line for the trader:** No fundamental developments on any of the six holdings since yesterday's builds warrant a rebuild — this is a mechanical price-roll cycle. The one genuinely new macro input this desk is flagging explicitly is the **10-year Treasury's move to ~4.95%, described by Bloomberg as "the cusp of 5%" and the highest level since 2007** (up from the ~4.84-4.85% this desk's last two WACC builds used as the risk-free input). See the rate-sensitivity note below each model — the move is real but, at ~10-11bps, too small on its own to flip any of today's five verdicts; it matters more as a second consecutive week of the risk-free rate moving the wrong direction for every one of this book's WACC estimates simultaneously, not as a one-day shock. Separately, a fresh DOJ probe into NVDA's Groq licensing arrangement is a new, as-yet-unquantifiable risk flag on NVDA (see §1) — not modeled into cash flows, since nothing here changes actual revenue/margin facts yet.

---

## Rate-sensitivity note (applies across all five priced models)
Risk-free rate (10yr Treasury) now reads **~4.95%** (Bloomberg, TradingEconomics — confirmed live this run), up from the ~4.84-4.85% this desk's GEHC (9/10) and XLE (9/9) builds used, and up from the ~4.6-4.7% range NVDA's (8/27) and OMCL's (7/30) older builds assumed. Equity risk premium (~5.0%) and each name's cost-of-debt assumptions are unchanged. Flowing a ~10-15bp risk-free increase through each capital structure moves modeled WACC by roughly **+7 to +12bps** — inside the noise band of these models (a full WACC point moves fair value by $10-25/sh on GEHC alone, per its own sensitivity table) and not large enough by itself to justify pulling forward a full rebuild on any name today. This desk is not moving any base-case WACC this run on a same-day reading; if the 10yr closes above 5% and holds there for a full week (a genuine regime change, not a single print), that is the trigger for a coordinated WACC rebuild across all five priced models, not just GEHC's.

---

## 1. NVIDIA (NVDA) — price-roll update, model unchanged; new non-cash risk flag

Price $219.4915 (state.md, 9/11 ~09:36 ET, +0.52% — part of today's broad relief rally, first all-green day for the book since 9/8). No fresh structural catalyst to the cash-flow build this run.

Base case fair value **$206.2** (WACC 11%, g 3% — unchanged since 8/27) vs. $219.4915 implies **~6.1% downside**, essentially flat vs. 9/10's ~5.8%.

**New this run**: WebSearch surfaced a **DOJ probe into NVDA's licensing deal with AI startup Groq**. This is a genuine new risk item — regulatory/antitrust scrutiny of a core AI-ecosystem relationship — but at this stage it's a headline, not a disclosed financial or contractual impact, so this desk is not modeling a probability-weighted haircut into the base case yet. Flagging it explicitly as a key assumption to watch (see below) rather than silently ignoring it.

### Verdict: **MILDLY OVERVALUED**
Hold, no add, no trim. Per state.md's 9/11 snapshot, NVDA sits at ~12.31% equity — comfortably below the 18-20% single-name trigger; NVDA+OMCL combined ~20.21%, buffer clean vs. the 25% trigger.

### Key assumptions that could break this model
- Upside break: the 70% FY28 guide proves genuinely supply-constrained (a floor, not a ceiling).
- Downside break: AVGO/hyperscaler custom-silicon competition erodes the 75% gross-margin assumption in years 3-5.
- **New**: the Groq DOJ probe escalates from a licensing-terms inquiry into something that constrains a genuine growth channel (custom-silicon licensing/partnerships) — worth a dedicated follow-up search once more detail is public; not sized into the model today.

---

## 2. Omnicell (OMCL) — price-roll update, model unchanged, discount at a new widest-recorded level

Price $32.88 (state.md, 9/11 ~09:36 ET, +1.95% — flagging a wide $32.88/$33.21 bid/ask per rule 4 rather than treating the last-trade tick as fully reliable). No fresh catalyst found this run beyond the already-known Q2 print and 10/29 next-earnings date; WebSearch this run only reconfirmed late-July/early-August sell-side price-target trims (Piper Sandler to $45, KeyBanc to $65, Wells Fargo to $50) already on file, not new information.

Base case fair value **$53.89** (WACC 9%, g 3% — unchanged since 7/30) vs. $32.88 implies **~63.9% upside** — a new widest-recorded gap on this name, up from 9/10's ~62.9%.

### Verdict: **UNDERVALUED — widest mispricing on the book, still gated**
No fresh catalyst to act on (rule 1); the OMCL DCA accumulated-profit gate (per state.md, ~$0.26 of the $2.50 threshold as of 9/11 09:36 ET) remains the operative timing mechanism, not this desk's valuation call.

### Key assumptions that could break this model (unchanged)
- Upside break: the softer Q3/bookings guide proves conservative rather than a genuine slowdown.
- Downside break: continued high-amplitude, no-catalyst price action remains an argument for sizing discipline, not for revising this desk's valuation call.

---

## 3. Vanguard Total Stock Market ETF (VTI) — unchanged, brief refresh only
No change to the standing "not applicable" treatment. $377.10 (+1.03%). This desk has no fair-value view on VTI and defers entirely to BR/BW on sizing and drift-band status.

## 4. Vanguard Total International Stock ETF (VXUS) — unchanged, brief refresh only
No change to the standing "not applicable" treatment. $87.205 (+1.07%). No fair-value case to add or trim. Defer to BR/BW.

---

## 5. Energy Select Sector SPDR (XLE) — price-roll on 9/9's rebuilt composite, model unchanged this run

Price $64.97 (+0.06%, essentially flat). Brent eased to ~$106.11/bbl today (-1.41% day-over-day per TradingEconomics) off this week's spike above $107, still historically elevated on the live Hormuz war premium — WTI still holds north of $100. No fresh XOM/CVX-specific data point found this run to justify re-running the two-name composite; rolling forward 9/9's rebuild (WACC 10.5%, g 1.5%, weighted composite fair value ≈ $58.9/sh — see 9/9's report or git history for the full CVX+XOM build methodology).

vs. $64.97 → **gap ≈ -10.3% overvalued**, essentially flat vs. 9/10's -10.1%.

### Verdict: **OVERVALUED, gap ≈ -10.3% — verdict and magnitude both essentially unchanged**
No trim (hedge thesis intact — XLE remains the book's structural hedge against the live Hormuz/tanker-war escalation, now including the overnight Bahrain Fifth Fleet base strike GS flagged this morning), no add (still overvalued on the rebuilt composite even with oil near multi-year highs — this desk's model already prices in an elevated, not merely spot-chasing, long-run energy assumption). Standing self-directed ask unchanged: extend the composite beyond XOM+CVX to 5-8 names for a more complete basket read.

### Key assumptions that could break this model (unchanged from 9/9)
- Upside break: the war premium proves stickier than modeled (Brent holding $95+ through 2027) — today's pullback to ~$106 from >$107 is still well inside that band, not a break.
- Downside break: a genuine, signed Hormuz de-escalation would collapse the war premium faster than modeled, widening the overvaluation gap.

---

## 0. GE HealthCare (GEHC) — price-roll on yesterday's fresh rebuild, model unchanged this run

Price $64.975 (state.md, 9/11 ~09:36 ET, +1.14% on the day, back above the $65 mandatory-revisit line for the first time since 9/9). No new structural development since yesterday's rebuild — WebSearch this run reconfirmed the Patient Care Solutions strategic review is still an open, undecided process (management still evaluating "continued ownership, a sale and other value-enhancing transactions" per the 7/29 Q2 call; PCS ran -13.5% organic and EBIT of -$26M last quarter, ~15% of group revenue) — nothing new since yesterday's §0 rebuild, which already fully incorporated this.

Base case fair value **$71.16/sh** (WACC 8.5%, g 3% — rebuilt 9/10, unchanged) vs. $64.975 → **≈ +9.5% upside**, narrowing slightly from 9/10's +10.8% purely on today's price recovery back above $65.

### Verdict: **UNDERVALUED, gap ≈ +9.5% — direction and magnitude essentially unchanged from yesterday's rebuild**
No trim, no add from this desk's chair. GEHC is already at BR's target satellite weight; the DCF gap alone has never been this book's sole trigger for sizing (rule 6 requires BW's independent risk sign-off too). The PCS strategic review remains the live two-sided catalyst flagged in yesterday's rebuild — still unresolved, still not sized into either direction of this base case.

### Key assumptions that could break this model (unchanged from 9/10's rebuild)
- Upside break: a clean PCS divestiture at a fair-to-generous multiple would remove a negative-margin, declining segment and could be modestly accretive beyond what this base case credits.
- Downside break: a discounted fire-sale, a multi-quarter distracting process, or continuing to subsidize a shrinking, negative-margin PCS segment would each pull fair value down from this base case.
- Net-debt data gap, unchanged: the ~$8.0B figure is BW's 10-Q-sourced number from 8/20, not re-verified this run.
- Rate sensitivity: see the rate-sensitivity note above — GEHC's WACC is the single most consequential lever in this model (a full point moves fair value $10-25/sh), and today's ~4.95% risk-free reading is the closest any of this desk's models has come to a genuine rate-driven WACC nudge, though still short of the "sustained above 5% for a week" bar this desk has set for a rebuild trigger.

---

## Cross-check with GS screener (analysts/gs-stock-screener.md, 2026-09-11 ~09:44 ET report)
GS's rank-1 slot remains XLE (already held) — no separate not-held name requires a build this cycle. GS independently corroborates this desk's own read: the 10yr's move to "cusp of 5%" is the most consequential macro fact of the morning (GS frames rule 6a's pause as "further from lifting" for a second consecutive week, consistent with this desk's own rate-sensitivity framing above), and the overnight Bahrain Fifth Fleet base strike is a genuine escalation-category change this desk is folding into XLE's hedge-thesis-intact framing rather than into the composite DCF itself (a geopolitical risk premium, not a cash-flow fundamental). GS also flags PTCT's post-guidance-raise pullback as a live, not-yet-cross-vetted setup worth this desk opening a DCF on if it persists — noted for a future run, no action this cycle (not a held name, no rule-6 gate cleared).

## Explicit read on trader's current positions (all six: NVDA, OMCL, VTI, VXUS, XLE, GEHC)
**GEHC**: hold, no trim, no add — DCF gap ~9.5% undervalued (narrowed slightly on today's price recovery), model unchanged since yesterday's rebuild.
**NVDA**: hold, no add, no trim — base-case DCF gap ~6.1% overvalued, essentially flat. New DOJ/Groq licensing-probe risk flag, not yet quantifiable.
**OMCL**: hold, no add from this desk's chair — DCF discount at a new widest-recorded level (~63.9%). The DCA plan's own profit-threshold gate remains the actual timing mechanism.
**VTI / VXUS**: hold, no valuation view — diversified core-sleeve holdings, not DCF calls. Defer to BR/BW on drift-band status.
**XLE**: hold, no trim, no add — composite fair value ≈ $58.9/sh, gap ≈ -10.3%, essentially flat vs. 9/10.

---

Sources:
- [Global Bond Selloff Sends 10-Year Treasury Yields to Cusp of 5% - Bloomberg](https://www.bloomberg.com/news/articles/2026-09-11/global-bond-selloff-sends-10-year-treasury-yields-to-cusp-of-5)
- [US 10 Year Treasury Note Yield - Trading Economics](https://tradingeconomics.com/united-states/government-bond-yield)
- [NVIDIA (NVDA) Stock Price, Quote, News & History - Benzinga](https://www.benzinga.com/quote/NVDA)
- [Omnicell, Inc. (OMCL) Latest Stock News & Headlines - Yahoo Finance](https://finance.yahoo.com/quote/OMCL/news/)
- [GE HealthCare could sell Patient Care Solutions biz as it reorganizes - MassDevice](https://www.massdevice.com/ge-healthcare-could-sell-patient-care-solutions-biz-as-it-reorganizes/)
- [GE HealthCare PCS: A Stronger Asset - Signify Research](https://www.signifyresearch.net/insights/ge-healthcares-patient-care-solutions-review-a-stronger-asset-than-the-numbers-suggest/)
- [Oil Just Topped $109. Is It Too Late to Buy Chevron (CVX)? - The Motley Fool](https://www.fool.com/investing/2026/09/10/oil-just-topped-usd109-is-it-too-late-to-buy-chevron-cvx-history-has-a-clear-answer/)
- [Brent oil - Price - Trading Economics](https://tradingeconomics.com/commodity/brent-crude-oil)
- Internal: trading-experiment/state.md (09:36 ET), analysts/gs-stock-screener.md (9/11 ~09:44 ET), analysts/bw-risk-assessment.md (9/10 ~14:41 ET), analysts/br-portfolio-builder.md (9/10 ~16:11 ET), analysts/jpm-earnings-analyzer.md (9/11)
